Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.
This meta-analysis of 16 cohort studies found that high body weight fluctuation is associated with increased risk of all-cause dementia, Alzheimer's disease, and vascular dementia, with hazard ratios ranging from 1.33 to 1.40 compared to stable weight. No significant association was found between weight variability and general cognitive decline, and evidence certainty was assessed using rigorous GRADE methodology.
This article examines how anti-amyloid monoclonal antibodies used to treat Alzheimer's disease may interact with or influence depression, a common comorbidity in elderly patients. The review discusses the neurobiological connections between amyloid pathology and mood disorders, and implications for treatment outcomes.
This review examines aspirin's potential therapeutic role in Alzheimer's disease by targeting neuroinflammation and oxidative stress, two key pathological mechanisms in cognitive decline. The article discusses aspirin's multi-target pharmacological properties beyond its conventional anti-inflammatory COX inhibition, proposing it as a basis for developing disease-modifying treatments.
This review examines two disease-modifying monoclonal antibodies—lecanemab and donanemab—that target amyloid-beta pathology in early-stage Alzheimer's disease, showing modest cognitive decline reductions (27-29%) over 18-76 months in clinical trials. Key challenges addressed include variable efficacy across demographic groups, amyloid-related imaging abnormalities, cost barriers, and the need for more inclusive research and personalized treatment approaches.
This review examines death-associated protein kinase 1 (DAPK1) as a promising therapeutic target for Alzheimer's disease, exploring its involvement in key pathogenic mechanisms including amyloid-beta accumulation, tau phosphorylation, neuronal cell death, and mitochondrial dysfunction. The authors discuss potential treatment strategies using small molecules, microRNAs, and natural compounds that could modulate DAPK1 activity.